Novanta Acquires Riverpoint Medical for Growth

Novanta has finalized its acquisition of Riverpoint Medical, a move poised to significantly expand its footprint in the high-growth minimally invasive surgical consumables market. This strategic integration, previously held by private equity firm Arlington Capital Partners, is expected to nearly double Novanta’s recurring medical consumables revenue, projecting it to reach approximately $300 million. The transaction also elevates the contribution of the medical end-market to 60% of Novanta’s total revenue, underscoring a sharpened focus on this vital sector.

Riverpoint Medical distinguishes itself through proprietary material science and advanced coating technologies, including osteoconductive materials, crucial for orthopedic and cardiovascular applications. The company’s expertise extends to managing the entire 510(k) clearance process for its clients, a significant value-add for Original Equipment Manufacturers (OEMs). This capability, coupled with its portfolio of IP-protected, private-label products such as suture anchors, implantable materials, sutures, and surgical instruments, positions Riverpoint as a key player in sports medicine, trauma, and cardiovascular surgery.

The acquisition is projected to unlock an additional $2 billion in addressable market opportunities by leveraging shared OEM customer relationships. Furthermore, it enhances Novanta’s manufacturing capabilities with Riverpoint’s FDA-registered facilities in Portland, Oregon, and San Jose, Costa Rica. This expanded, geographically diversified manufacturing base is critical for ensuring supply chain resilience and meeting the stringent demands of the medical device industry, a sector that saw global market size for surgical consumables estimated at over $50 billion in recent years and is projected for continued robust growth.

Financial projections indicate a strong return on investment, with a high single-digit return anticipated by year three and achievement of the company’s hurdle rate by year five. The deal is immediately accretive to Novanta’s organic growth, adjusted gross margins, adjusted EBITDA, and cash flows. Specifically, the transaction is expected to contribute between $0.18 and $0.25 to adjusted earnings per share in 2027, the first full fiscal year post-completion. Further financial details impacting 2026 performance will be disclosed during Novanta’s upcoming second-quarter earnings call.

Matthijs Glastra, Chair and CEO of Novanta, highlighted the strategic importance of the acquisition, stating, “Riverpoint Medical is a market-leading, high-growth surgical consumables business growing revenue and cash flow at twice Novanta’s rate.” He further emphasized the dual benefit of increased revenue and market access, noting, “Beyond the top-line boost, we believe the deal unlocks a $2 billion incremental addressable market through shared OEM customer relationships and strengthens Novanta’s regional, FDA-registered manufacturing footprint, positioning the overall company for accelerated, higher-margin growth.”

The integration of Riverpoint Medical into Novanta’s Medical Solutions operating segment signifies a strategic pivot towards higher-margin, recurring revenue streams within the healthcare technology and medical device manufacturing space. This move aligns with broader industry trends favoring specialized suppliers capable of offering integrated solutions, from material science innovation to regulatory compliance and scalable manufacturing.